VENUS CONCEPT INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6843 USD | -11.00% |
|
-16.04% | -42.01% |
| 04-08 | Venus Concept Inc. Announces Israeli Regulatory Approval for Venus Bliss MAX | CI |
| 04-01 | Transcript : Venus Concept Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
| Sales 2024 * | 72.47M 5.8B | Sales 2025 * | 79.43M 6.36B | Capitalization | 4.35M 348M |
|---|---|---|---|---|---|
| Net income 2024 * | -31M -2.48B | Net income 2025 * | -23M -1.84B | EV / Sales 2024 * | 0.06 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.05 x |
| P/E ratio 2024 * |
-0.15
x | P/E ratio 2025 * |
-0.41
x | Employees | 304 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Venus Concept Inc.
More recommendations
More press releases
| 1 day | -11.00% | ||
| 1 week | -16.04% | ||
| Current month | -0.97% | ||
| 1 month | -2.95% | ||
| 3 months | -44.81% | ||
| 6 months | -68.47% | ||
| Current year | -42.01% |
1 week
0.68
0.90
1 month
0.610.90
Current year
0.602.22
1 year
0.604.70
3 years
0.6050.55
5 years
0.60135.00
10 years
0.60135.00
| Managers | Title | Age | Since |
|---|---|---|---|
Rajiv De Silva
CEO | Chief Executive Officer | 58 | 01/10/22 |
| Director of Finance/CFO | 63 | 31/08/17 | |
| President | 49 | 16/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Keith Sullivan
BRD | Director/Board Member | 66 | 30/06/18 |
Anthony Natale
BRD | Director/Board Member | 51 | 31/10/19 |
Louise Lacchin
BRD | Director/Board Member | 67 | 31/07/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.6843 | -11.00% | 23,157 |
| 25/04/24 | 0.7689 | +6.66% | 26,979 |
| 24/04/24 | 0.7209 | -5.14% | 10,150 |
| 23/04/24 | 0.76 | -9.98% | 18,975 |
| 22/04/24 | 0.8443 | +3.60% | 24,743 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Venus Concept Inc. is a global medical aesthetic technology company. The Company has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches in over 60 countries and 14 direct markets. The Company's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. The Company's systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry's traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company's hair loss treatment solutions include the ARTAS Solution and the NeoGraft Solution.
Calendar
14/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.6843
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.01% | 4.35M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- VERO Stock
